Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen QuantideX NGS Data Hotspot 21 RUO Kit

Asuragen announced the CE marking and launch of its QuantideX NGS DNA Hotspot 21 Kit, a targeted next-generation sequencing panel to detect variants across a multitude of tumor types. By screening for the most commonly observed variants in a simplified workflow, the research-use-only kit addresses current clinical and laboratory challenges regarding NGS testing such as long time-to-result, high assay complexiity, and lengthy data interpretation.

The assay includes the firm's cGMP manufactured, end-to-end NGS-in-a-box design, providing the reagents needed to prepare sequencing-ready libraries in as little as 24 hours. The firm's bioinformatics software examines whether enough amplifiable DNA exists. 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.